The short answer: for most healthy women under 60, or within ten years of the start of menopause, current medical guidance says the benefits of hormone therapy outweigh the risks. That is the position of The Menopause Society, and as of 2026 the FDA has removed most of its strongest warnings from these medications. Hormone therapy is still the wrong choice for some women, including those with a history of hormone-sensitive breast cancer or blood clots, which is why we look at your health history and labs before anyone writes a prescription.
If you're hesitant about hormone therapy, there's a good chance the hesitation traces back to one study from 2002. We hear it in consults every week, sometimes from patients whose perimenopause symptoms were dismissed for years, sometimes from their mothers. So this post walks through what that study found, what two decades of follow-up research changed, and where the real risks still sit.
Why a generation of women was told hormones are dangerous
In July 2002, the Women's Health Initiative (WHI), a large federally funded trial, stopped its combined estrogen and progestin arm three years early. The study had enrolled 16,608 women ages 50 to 79, all with a uterus, and randomized them to a placebo or to Prempro, a pill combining conjugated equine estrogens with medroxyprogesterone acetate, a synthetic progestin. After an average of 5.2 years, the safety board saw more invasive breast cancers, heart events, strokes, and blood clots in the hormone group and shut the arm down.
That press coverage is why your mother, or your own doctor in 2005, may have told you hormones cause cancer. Headlines reported a 26 percent increase in breast cancer risk. Prescriptions collapsed, and a generation of women white-knuckled through hot flashes, broken sleep, and bone loss because the treatment looked scarier than the symptoms.
The problem is what those headlines left out.
What the 2002 study actually found
That 26 percent figure was a relative risk. In absolute terms, the WHI found eight additional invasive breast cancers per 10,000 women per year of combined hormone use. Spread across 1,250 women taking hormones for a full year, that is one extra case. The same report counted seven extra heart events, eight extra strokes, and eight extra pulmonary embolisms per 10,000 women per year, alongside six fewer colorectal cancers and five fewer hip fractures.
Those are real numbers, worth taking seriously. But "one extra case per 1,250 women per year" and "26 percent more cancer" describe the same data, and only one of them emptied pharmacy shelves. The breast cancer finding also sat right at the edge of statistical significance, a detail that rarely made the evening news.
There were two bigger issues. First, the average WHI participant was 63 years old, and many were a decade or two past menopause. Those results were then applied to 51-year-olds just entering it. Second, the trial tested one specific pill at one dose. The WHI's separate estrogen-only arm, for women who had a hysterectomy, told a different story. In long-term follow-up, those women had fewer breast cancers than the placebo group.
What twenty years of re-analysis changed
Researchers went back into the WHI data and sorted it by age. Women who started hormones in their 50s, close to the beginning of menopause, showed a meaningfully better risk profile than women who started in their 60s and 70s. This became known as the timing hypothesis: when you start matters about as much as whether you start.
That thinking is now mainstream. The Menopause Society's 2022 position statement concludes that for women under 60 or within 10 years of menopause onset who have no contraindications, benefits outweigh risks for treating hot flashes and night sweats and for preventing bone loss. It also dropped the old assumption that everyone must quit at 60 or 65. Continuing became a case-by-case decision.
The FDA followed. In November 2025 the agency announced it would remove the boxed warnings, the strongest warning it issues, from hormone therapy products, saying the cardiovascular disease, breast cancer, and dementia language rested on outdated readings of the WHI. The first revised labels were approved in February 2026. Two caveats worth knowing: the endometrial cancer warning stays on systemic estrogen-only products, and some clinicians argued the removal went further than the evidence supports. Regulators can overswing in either direction, one more reason to weigh your own risk profile over the headlines.
The risks that haven't gone away
None of this means hormone therapy is risk-free. It isn't, and we won't tell you otherwise.
Combined estrogen and progestogen therapy still carries a small increase in breast cancer risk that grows with years of use. The UK's National Health Service puts it at around five extra cases per 1,000 women who take combined HRT for five years. Estrogen taken as a pill raises blood clot risk; estrogen absorbed through the skin does not appear to, which makes delivery method part of the safety conversation. And a woman with a uterus who takes estrogen needs a progestogen with it, because unopposed estrogen raises endometrial cancer risk.
Then there's the group we'd talk out of systemic hormone therapy altogether, or send back to their specialist first:
- A history of hormone-sensitive cancer. Estrogen can stimulate leftover hormone-receptor-positive breast cancer cells and can work against endocrine treatments like tamoxifen. The same caution applies to endometrial cancer.
- A history of blood clots or a clotting disorder. A prior DVT, a pulmonary embolism, or a diagnosed thrombophilia changes the math, especially for oral estrogen.
- A prior stroke or heart attack. Cardiovascular history shifts the balance and calls for cardiology input first.
- Unexplained vaginal bleeding or active liver disease. Both need a diagnosis before any hormone prescription makes sense.
Women in these groups still have options. Low-dose vaginal estrogen is minimally absorbed and often reasonable for genitourinary symptoms, and nonhormonal prescriptions exist for hot flashes. If a treatment isn't safe for you, our job is to say so and help you find one that is.
What "safe" looks like in practice
Safety in hormone therapy is mostly a process, and the process is boring on purpose. At Aspire Health we don't prescribe from a symptom checklist. We start with a full health history and baseline labs, and when symptoms and blood work don't line up, a DUTCH test can show how your body is actually processing its hormones. If treatment makes sense, we use the lowest dose that controls symptoms, recheck labs to confirm levels landed where we intended, and revisit the whole plan at least once a year. Mammograms and routine screening stay on schedule. Hormone therapy never replaces them.
One more piece of honesty, since we offer bioidentical hormone replacement therapy: "bioidentical" means the hormone is chemically identical to what your body makes, such as estradiol or micronized progesterone, both available in FDA-approved products. The word does not mean risk-free, and compounded versions have not been shown to be safer than FDA-approved ones. Marketing that treats "bioidentical" as a magic safety word deserves your skepticism, ours included.
Most of the research above concerns women in menopause. Testosterone therapy for men is a separate evidence base; we cover it in our post on low testosterone signs, testing, and treatment.
Common questions about hormone therapy safety
Does HRT cause breast cancer?
Combined estrogen and progestogen therapy carries a small increase in risk, roughly five extra cases per 1,000 women over five years of use, and it rises the longer you use it. Estrogen-only therapy, an option after hysterectomy, was linked to fewer breast cancers in the WHI's long-term follow-up. A personal history of hormone-receptor-positive breast cancer is a different situation entirely, and systemic hormone therapy is generally avoided there.
How long can you safely stay on hormone therapy?
There is no fixed expiration date anymore. Current Menopause Society guidance replaced the automatic cutoff at 60 or 65 with an annual review of whether symptoms persist, whether your health history has changed, and whether benefits still outweigh risks at your age and dose. Many women taper off when symptoms fade. Some continue longer for quality of life or bone protection. The requirement is a yearly review with current labs.
Why did the FDA remove the black box warning?
The FDA concluded the boxed warnings about cardiovascular disease, breast cancer, and probable dementia overstated the evidence for today's typical patient: a woman starting therapy near menopause, rather than a decade or more after it. Revised labels began rolling out in February 2026 with age-specific guidance. The endometrial cancer warning remains on systemic estrogen-only products, and some clinicians pushed back on the change. Either way, the label matters less than your individual risk profile.